ACTRN12609000643279已完成2 期
A phase 2 trial evaluating the effect of Everolimus alternating with Sunitinib on progression-free survival in patients with advanced renal cell carcinoma.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patients will be eligible for enrollment if they fulfill all of the following criteria:
- •1. Renal cell carcinoma with a clear cell component confirmed by histology or cytology
- •2. Advanced disease: metastatic OR locally advanced OR locally recurrent; AND, not suitable for resection
- •3. Male or female, aged 18 years or older
- •4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •5. Low or intermediate Memorial Sloan Kettering Cancer Center (MSKCC) prognostic risk score (8, 9), i.e. no more than 2 of the following: Karnofsky performance status 1.5 times institutional upper limit of normal; Anaemia (haemoglobin less than institutional lower limit of normal); Hypercalcemia (corrected serum calcium >2.5 mmol/L); Interval since diagnosis less than 1 year.
- •6. Target and/or non-target lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (15). Patients participating in Positron Emission Tomography (PET) studies must have a lesion assessable by PET (at least 2cm in diameter in an organ not subject to undue PET artefact, as determined by the site Principal Investigator in conjunction with nuclear medicine physicians).
- •7. Expected survival of at least 3 months.
- •8. Within 3 weeks prior to registration, vital laboratory parameters should be within the normal range, except for the following parameters, which should be within the ranges specified: Neutrophils >/= 1.5 x 109/L; Platelets >/= 90 x 109/L; International Normalised Ratio (INR) 9. Left ventricular ejection fraction >/= 55% on gated cardiac blood pool scan, or normal left ventricular function and fractional shortening on echocardiogram (according to institutional limits).
- •10. Systolic blood pressure 11. Able to commence treatment within 7 days of registration.
- •12. Willing and able to comply with follow-up and all other protocol requirements.
- •13. Written informed consent
排除标准
- •Patients will be excluded from the study for any of the following reasons:
- •1. Prior treatment with Vascular Endothelial Growth Factor (VEGF)-targeting agents (e.g. bevacizumab) or multi-kinase inhibitors (e.g. sorafenib or sunitinib), or mammalian Target of Rapamycin (mTOR)-targeting agents (e.g. everolimus or temsirolimus).
- •2. Active central nervous system metastases. Patients may be eligible if they have central nervous system metastases that have been adequately treated (surgery or radiotherapy), do not require ongoing corticosteroids for control of symptoms, and have had no evidence of progression for at least three months.
- •3. Other malignancy diagnosed within the last 5 years, except the following if adequately treated: superficial Squamous Cell Carcinoma (SCC) or Basal Cell Carcinoma (BCC) of skin, superficial bladder cancer (T1 and G1 or T1 and G2), stage 1 cervical cancer.
- •4. Treatment with an investigational agent in the last 4 weeks.
- •5. Known to be Human Immunodeficiency Virus (HIV) positive (testing not mandatory unless clinically indicated).
- •6. Evidence of chronic hepatitis due to Hepatitis B Virus (HBV) (HBV surface antigen positive) or Hepatitis C Virus (HCV) (HCV ribonucleic acid (RNA) positive). All potential participants will be tested for HBV surface antigen, HBV core antibody, HCV antibody, and HCV RNA if the HCV Ab is positive.
- •7. Clinically significant heart disease (New York Heart Association (NYHA) Class III or IV).
- •8. History of hypertension requiring hospitalisation.
- •9. Other serious illnesses, e.g. active infection requiring antibiotics, bleeding disorders.
- •10. Immunotherapy or chemotherapy in the last 4 weeks (6 weeks for nitrosoureas).
- •11. Major surgery in the last 4 weeks, or planned in the next 6 weeks.
- •12. Radiation therapy in the last 2 weeks, or planned in the next 6 weeks. Any acute adverse effects of recent radiation must have resolved prior to registration. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one lesion that has not been irradiated or which has progressed following radiotherapy.
- •13. National Cancer Institute of the USA Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 grade 3 or worse haemorrhage in last 4 weeks.
- •14. Any of the following in the last year: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
- •15. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication.
- •16. Ongoing cardiac dysrhythmias of NCI CTCAE version 4.0 grade =2, atrial fibrillation of any grade, or prolongation of the corrected QT interval (QTc) to >450 msec for males or >470 msec for females.
- •17. Uncontrolled diabetes as defined by fasting serum glucose >1.5 X Upper Limit of Normal (ULN).
- •18. Pregnancy (negative pregnancy test required for women of child-bearing potential), lactation
- •19. Inadequate contraception. Women must be post-menopausal, surgically sterile, or use 2 reliable forms of contraception. Men must be surgically sterile or use a barrier method of contraception.
- •20. Known allergy or hypersensitivity to everolimus, sunitinib or iodine.
- •21. Medical or psychiatric condition that compromises the patient's ability to give informed consent.
研究者
相似试验
进行中（未招募）
不适用
evaluation of the activity of Everolimus as maintenance therapy for metastatic neuroendocrine carcinoma with pulmonary or gastroenteropancreatic origin.The aim of this study is to evaluate the activity of a maintenance therapy with everolimus 10 mg daily in patients with stable disease, partial response or complete response after 6 cycles of induction chemotherapy with cisplatin or carboplatin plus etoposide administered according to clinical practice.EUCTR2014-003951-72-ITGruppo Oncologico Italiano Ricerca Cancro (GOIRC)
已完成
2 期
A multicenter phase II trial of everolimus for unresectable pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based regimenresectable pancreatic neuroendocrine carcinomaJPRN-UMIN000012752ational Cancer Center Hospital East25
进行中（未招募）
1 期
A trial to investigate the use of Veregen ointment in the treatment of vulval intraepithelial neoplasia, a severe skin disorder that may lead to vulval cancer.Vulval intraepithelial neoplasia (VIN)MedDRA version: 16.1Level: LLTClassification code 10057313Term: Vulval intraepithelial neoplasia grade IIISystem Organ Class: 100000004864EUCTR2013-003107-19-GBniversity of Birmingham26
进行中（未招募）
1 期
Phase II trial evaluating the efficacy of durvalumab (MEDI4736) as second-line therapy in Non- Small-Cell Lung Cancer patients receiving concomitant steroidson- Small-Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10025122Term: Lung squamous cell carcinoma stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003645-41-ITFONDAZIONE RICERCA TRASLAZIONALE84
招募中
2 期
Randomized, placebo-controlled phase II study of efficacy of morphine for dyspnea in patients with interstitial lung disease: JORTC-PAL15Interstitial lung diseaseJPRN-jRCTs051190030Matsuda Yoshinobu50